Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults
- 13 August 2009
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 27 (37), 5091-5095
- https://doi.org/10.1016/j.vaccine.2009.06.057
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B CellsPLOS ONE, 2008
- Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine after Priming with an Antigenic VariantThe Journal of Infectious Diseases, 2008
- Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in AdultsThe Journal of Infectious Diseases, 2008
- Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in HumansThe Journal of Infectious Diseases, 2008
- Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine PreparationsClinical Infectious Diseases, 2006
- Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) VaccineNew England Journal of Medicine, 2006
- Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic useVirus Research, 2004
- MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profileExpert Review of Vaccines, 2003
- Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccinesMedical Microbiology and Immunology, 2002
- Antibody induction by influenza vaccines in the elderly: a review of the literatureVaccine, 1989